Clinical trials: Oral Anticoagulants
Simulation Training, Anticoagulant Drugs
E-learning to Improve Oral Anticoagulant Use in Hospitalized Older People With AF
Atrial Fibrillation (AF) is the most common cardiac arrhythmia and the main cause of cardioembolic stroke. Oral Anticoagulation (OAC) has been shown to significantly prevent AF-related thromboembolism, however, despite convincing…
- Conditions
- Simulation Training, Anticoagulant Drugs, Elderly, Atrial Fibrillation
- Trial name
- SIM-AF (NCT03188211)
- Testing
- E-learning educational program, Control
- Where
- 20 sites in Italy
- Volunteers
- 247 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Anticoagulants and Bleeding Disorders, Surgery
Oral Surgery in Patients Taking Direct Oral Anticoagulants
This study evaluates the incidence of postoperative bleeding after oral surgical procedures in patients taking direct oral anticoagulants and in patients taking vitamin K antagonists.
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Postoperative Hemorrhage, Dentoalveolar Haemorrhage
- Trial name
- OSDOA (NCT04505475)
- Testing
- Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)
- Where
- Serbia
- Volunteers
- 82 people
- Sponsor
- University of Novi Sad
Atrial Fibrillation
Atrial Fibrillation in Turkey: Epidemiologic Registry-2
Atrial fibrillation (AF) is one of the most common cause of preventable ischemic stroke and associated with increased cardiovascular morbidity and mortality.
- Trial name
- AFTER-2 (NCT02354456)
- Where
- Turkey (Türkiye)
- Volunteers
- 4,100 people
- Sponsor
- Dicle University
Ischemia, Stroke
Edoxaban for TIA and Acute Minor Stroke
Transient ischemic attack (TIA) or minor ischemic stroke has a high risk of early recurrent stroke. As the golden standard, aspirin effect modestly on acute ischemic stroke, and slightly increase the risk of intracerebral…
- Conditions
- Ischemia, Stroke, Cerebral Infarction
- Trial name
- NCT02221102
- Testing
- Aspirin, edoxaban
- Where
- China
- Volunteers
- 3,700 people
- Sponsor
- Xijing Hospital
Atrial Fibrillation, Anticoagulant Adverse Reaction
Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
In this clinical trial, Rivaroxaban of standard dose (20mg) and reduced dose (15mg) will be administeted in non-valvular atrial fibrillation patients without severe renal dysfunction.
- Trial name
- REVISE-AF (NCT06187311)
- Testing
- Rivaroxaban 20 MG, Rivaroxaban 15 MG
- Where
- South Korea
- Volunteers
- 940 people
- Sponsor
- Korea University Anam Hospital
Venous Thromboembolism, Major Bleed
Direct Oral Anticoagulants and Venous Thromboembolism
The purpose of this study is to determine whether use of direct oral anticoagulants (DOACs) is associated with an increased risk of major bleeding compared to warfarin use, for the treatment of venous thromboembolism (VTE).
- Trial name
- NCT02833987
- Testing
- Apixaban (ATC B01AF02), Dabigatran (ATC B01AE07), Rivaroxaban (ATC B01AF01)
- Where
- Canada
- Volunteers
- 59,525 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Heart Failure
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
Evaluation of the risk factors associated with Heart Failure (HF) worsening (measured by hospitalizations and emergency visits because of HF exacerbations) in Spanish patients with Atrial Fibrilation and HF treated with…
- Trial name
- FARAONIC (NCT03455439)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Spain
- Volunteers
- 552 people
- Sponsor
- Bayer
Thrombotic Stroke, Atrial Fibrillation and Flutter
ReAl-life Multicentre Survey Evaluating Stroke Prevention Strategies (RAMSES)
The aim of this study is to evaluate the present status of stroke prevention strategies in patients with non-valvular atrial fibrillation (NVAF).
- Trial name
- RAMSES (NCT02344901)
- Where
- 62 sites in Turkey (Türkiye)
- Volunteers
- 6,273 people
- Sponsor
- Muğla Sıtkı Koçman University
Anticoagulation With NOAC
Specific PoC Testing of Coagulation in Patients Treated With DOAC 1
The investigators study aims to test the correlation between the Cascade Abrazo point-of-care testing (POCT) device (Helena Laboratories, USA) and plasma levels of apixaban, dabigatran, edoxaban and rivaroxaban, and to determine…
- Trial name
- SPOCT-DOAC 1 (NCT02825394)
- Testing
- anti-Xa activity point-of-care testing (aXa-POCT), ecarin clotting time point-of-care testing (ECT-POCT)
- Where
- Germany
- Volunteers
- 160 people
- Sponsor
- University Hospital Tuebingen
Total Knee Arthroplasty, Venous Thromboembolism
Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty
Yes. For these two fields, I would enter the following in English, based on your study protocol. 1. Brief Summary Copy and paste: This study aims to compare three thromboprophylaxis regimens in adults undergoing primary total…
- Trial name
- DOLOTHROK (NCT07869615)
- Testing
- Apixaban, Rivaroxaban, Enoxaparin (LMWH)
- Where
- Tunisia
- Volunteers
- 138 people
- Sponsor
- Military Hospital of Tunis
Healthcare Quality Indicators, Inappropriate Prescribing
Development and Validation of Automated Indicators on the Appropriateness of Oral Anticoagulant Prescriptions
This research focuses on the development and validation of indicators on the appropriateness of oral anticoagulant prescriptions.
- Conditions
- Healthcare Quality Indicators, Inappropriate Prescribing, Anticoagulant Drugs, Atrial Fibrillation
- Trial name
- PACHA (NCT02898090)
- Where
- 4 sites in France
- Volunteers
- 1,213 people
- Sponsor
- University Hospital, Bordeaux
Venous Thromboembolism
Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs
To assess the safety and pharmacokinetics of DU-176b administered to patients with severe renal impairment undergoing orthopedic surgery of the lower limbs, compared with DU-176b administered to patients with mild renal…
- Trial name
- NCT01857583
- Testing
- 15mg DU-176b, 30mg DU-176b, Fondaparinux
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Epistaxis
Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence Risk Factors at a Tertiary Care Hospital in Nepal
This study aims to determine the prevalence of epistaxis and identify the associated risk factors among patients receiving oral anticoagulants and antiplatelet at a tertiary care hospital in Nepal.
- Trial name
- Epistaxis (NCT06906861)
- Where
- Nepal
- Volunteers
- 284 people
- Sponsor
- Institute of medicine, Maharagjung medical campus
Direct Oral Anticoagulants (DOACs)
LED Application Following Dental Extraction in Patients Taking Direct Oral Anticoagulants.
The DENT-DOAC trial is a single-blinded RCT investigating the effectiveness of LED application following dental extractions in patients taking direct oral anticoagulants (DOACs) .
- Trial name
- DENT-DOAC (NCT06971081)
- Testing
- LED light
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Venous Thromboembolism
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.
- Trial name
- VTE (NCT04041843)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York Medical College
Adherence, Medication, Statin Adverse Reaction
Medicines Gaps Study
The adherence project aims to understand adherence rates and barriers to Direct oral anticoagulants (DOACs) and statins and improve awareness of healthcare professionals on adherence across Leeds.
- Conditions
- Adherence, Medication, Statin Adverse Reaction, Anticoagulant Adverse Reaction
- Trial name
- MeGa (NCT05332158)
- Testing
- Questionnaires to report barriers to medication adherence
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Blood Transfusion, Hip Fracture Surgeries
Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs
This study looks at patients with hip fractures who are taking direct oral anticoagulants (DOACs), a type of blood thinner. In many hospitals, surgery for these patients is delayed because of concerns about bleeding, but waiting…
- Conditions
- Blood Transfusion, Hip Fracture Surgeries, Geriatric, Bleeding Complications
- Trial name
- OPTIMIZEDOAC (NCT07309848)
- Where
- 7 sites in Netherlands
- Volunteers
- 374 people
- Sponsor
- St. Antonius Hospital
Anticoagulation With Direct Oral Anticoagulants
Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Extended
The investigators' study aims to test the correlation between CoaguChek point-of-care aPTT testing (Roche, Switzerland) and low plasma levels of all four currently EMA approved direct oral anticoagulants (DOAC; apixaban…
- Trial name
- POCT-DOAC ext (NCT04679298)
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital Tuebingen
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅱ (NCT07007143)
- Testing
- Experimental: Aspirin monotherapy, Active Comparator: Aspirin+Clopidogrel
- Where
- China
- Volunteers
- 1,032 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Venous Thromboembolism
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.
Patients with unprovoked venous thromboembolism (VTE) or VTE associated with persistent risk factors have a high risk of recurrence after stopping anticoagulation.
- Trial name
- RENOVE (NCT03285438)
- Testing
- Reduced dose of DOAC, Full dose of DOAC
- Where
- 39 sites in France
- Volunteers
- 2,774 people
- Sponsor
- University Hospital, Brest